Open AccessDo you believe that N-of-1 trials (a clinical trial in which a single patient is the entire trial), are appropriate to evaluate the effectiveness of genomic therapies for rare and/or common genetic disorders? Do gene-editing/targeting therapies have the potential to expedite the advancement of personalized medicine?
Author(s) -
Ronald F. Carter
Publication year - 2017
Publication title -
health science inquiry
Language(s) - English
Resource type - Journals
ISSN - 2562-7791
DOI - 10.29173/hsi223
Subject(s) - clinical trial , medicine